Investor Relations

Corporate Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. 
 
Urovant recently reported positive long-term data for its lead product candidate, vibegron, an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB). The extension of the 12-week pivotal phase 3 EMPOWUR study demonstrated a favorable long-term safety and tolerability profile for vibegron and further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period. 
 
Vibegron is also being evaluated in a phase 3 study for the treatment of OAB in men with benign prostatic hyperplasia and in a phase 2a study for abdominal pain associated with irritable bowel syndrome. 
 
Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy and Urovant Sciences intends to develop novel treatments for additional urologic diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
August 13, 2020
Urovant Sciences Reports Fiscal First Quarter 2020 Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 13, 2020-- Urovant Sciences (Nasdaq: UROV)   today reported financial results for the three months ended June 30, 2020 . The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked
Additional Formats
June 18, 2020
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 18, 2020-- Urovant Sciences (Nasdaq: UROV)   today reported financial results for the three months and 2019 fiscal year ended March 31, 2020 . The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences ,
Additional Formats
Events